The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Abroad (travel likely)RecruitingPHASE2

Conditions

Kidney Transplant Recipients

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Toronto General Hospital, Toronto, Ontario, Canada
Contact: Study coordinator (Vesta Lai) · vesta.lai@uhn.ca · 416-340-4800

Study leads

Sunita Singh, MD MSc FRCPC
Principal Investigator
University Health Network, Toronto General Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)

Kidney Transplant · Overweight or Obese Adults · Glucose Control

Abroad (travel likely)Recruiting

Kansas City, United States

Vascular Complications After Kidney Transplantation

Kidney Transplant Recipient · Kidney Transplant; Complications · Transplant Renal Artery Stenosis

Abroad (travel likely)Recruiting

Aarhus, Denmark · Copenhagen, Denmark

Personalized Stories for Pediatric Kidney Recipients

Kidney Transplant

Abroad (travel likely)Recruiting

Paris, France

Velocity-Based Resistance Training in Kidney Transplant Recipients

Kidney Transplant Recipients · Metabolic Syndrome · Cardiovascular Risk Factors

Abroad (travel likely)Recruiting

Bogotá, Colombia